Dengue virus, Johnson & Johnson
Johnson & Johnson Ends Phase 2 Study For Dengue Antiviral Amid R&D Reprioritization
Johnson & Johnson has discontinued its Phase 2 study of mosnodenvir, an investigational antiviral candidate for dengue prevention, as part of a strategic shift in its R&D portfolio. Final efficacy data from the study will be available after analysis.
Boris Johnson claims he found bugging device
With Tuesday’s announcement, Eastern North Carolina adds to its reputation for large-scale pharmaceutical manufacturing, as ...
Cody Johnson was fatally shot while driving westbound on a freeway in Katy, Texas. Police have no leads into the ...
Hosted on MSN34m
Kim Mulkey Could Help Flau'jae Johnson Dust Angel Reese's LSU Legacy Courtesy of a Crucial Lesson"We aren't as close as we used to be," Angel Reese admitted about her ex-teammate Flau'jae Johnson. The post Kim Mulkey Could ...
Boris Johnson has said he regrets apologising for the so-called partygate scandal over lockdown-era gatherings in Downing ...
By Boris Johnson. Harper; 784 pages; $40. William Collins; £30. I t was 2008, during the global financial crisis. Boris Johnson was mayor of London. The political situ ...
Wells Fargo analysts cautioned that Johnson&Johnson (NYSE:JNJ) may lower its earnings guidance for 2024 when the company ...
Joining a growing number of Black female-owned businesses in the city of Birmingham, Tanya Pugh-Johnson has opened an art ...
Hosted on MSN3d
Johnson & Johnson's Q3 2024 Earnings: What to ExpectWith a market cap of $390 billion, New Brunswick, New Jersey-based Johnson & Johnson (JNJ) is a leading healthcare company. Operating across the pharmaceuticals, medical devices, and consumer products ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback